[go: up one dir, main page]

NO20035848L - Nye vevsfaktorrettede antistoffer som antikoagulanter - Google Patents

Nye vevsfaktorrettede antistoffer som antikoagulanter

Info

Publication number
NO20035848L
NO20035848L NO20035848A NO20035848A NO20035848L NO 20035848 L NO20035848 L NO 20035848L NO 20035848 A NO20035848 A NO 20035848A NO 20035848 A NO20035848 A NO 20035848A NO 20035848 L NO20035848 L NO 20035848L
Authority
NO
Norway
Prior art keywords
anticoagulants
tissue factor
new tissue
directed antibodies
antibodies
Prior art date
Application number
NO20035848A
Other languages
English (en)
Inventor
David R Light
Kirk Mclean
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20035848(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20035848L publication Critical patent/NO20035848L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20035848A 2002-05-01 2003-12-30 Nye vevsfaktorrettede antistoffer som antikoagulanter NO20035848L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37656602P 2002-05-01 2002-05-01
PCT/US2003/013521 WO2003093422A2 (en) 2002-05-01 2003-04-30 Novel tissue factor targeted antibodies as anticoagulants

Publications (1)

Publication Number Publication Date
NO20035848L true NO20035848L (no) 2004-02-27

Family

ID=29401364

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20035848A NO20035848L (no) 2002-05-01 2003-12-30 Nye vevsfaktorrettede antistoffer som antikoagulanter
NO20035849A NO20035849L (no) 2002-05-01 2003-12-30 Nye vevsfaktorrettede trombomodulinfusjonsproteiner som antikoagulanter

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20035849A NO20035849L (no) 2002-05-01 2003-12-30 Nye vevsfaktorrettede trombomodulinfusjonsproteiner som antikoagulanter

Country Status (29)

Country Link
US (3) US7250168B2 (no)
EP (2) EP1549341B1 (no)
JP (2) JP4567437B2 (no)
KR (2) KR101013697B1 (no)
CN (2) CN100412090C (no)
AR (1) AR039515A1 (no)
AT (2) ATE427121T1 (no)
AU (2) AU2003225256B2 (no)
BR (2) BR0304660A (no)
CA (2) CA2483910A1 (no)
CR (1) CR7584A (no)
DE (2) DE60334538D1 (no)
DK (2) DK1549341T3 (no)
EC (2) ECSP045468A (no)
ES (2) ES2323056T3 (no)
HK (1) HK1080372A1 (no)
IL (3) IL164733A0 (no)
MX (2) MXPA04010795A (no)
NO (2) NO20035848L (no)
NZ (2) NZ536242A (no)
PE (1) PE20040597A1 (no)
PL (2) PL373945A1 (no)
PT (2) PT1549341E (no)
RS (2) RS104504A (no)
RU (2) RU2345789C2 (no)
TW (1) TWI343388B (no)
UA (2) UA81114C2 (no)
WO (2) WO2003092602A2 (no)
ZA (2) ZA200409692B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455852T1 (de) 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
AU7445900A (en) * 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
AU2001296305B2 (en) 2000-09-26 2007-12-06 Duke University RNA aptamers and methods for identifying the same
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
BR0304660A (pt) * 2002-05-01 2005-06-07 Schering Ag Anticorpos direcionados a fator de tecido como anticoagulantes
CA2490280A1 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7833978B2 (en) * 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
CN103045601B (zh) 2004-04-22 2015-04-01 雷加多生物科学公司 改良的凝血因子调节物
EP1889908A4 (en) 2005-06-03 2012-04-25 Mochida Pharm Co Ltd PROTEIN FUSED WITH ANTI-CD14 ANTIBODY
WO2008039206A2 (en) * 2005-10-05 2008-04-03 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
US20110040073A1 (en) * 2006-04-07 2011-02-17 Novo Nordisk Healthcare A/G Covalent Factor VII-Tissue Factor Complex
PE20080333A1 (es) 2006-06-08 2008-06-15 Chugai Pharmaceutical Co Ltd Agentes para prevenir o tratar enfermedades inflamatorias
CN101522206B (zh) * 2006-10-06 2013-03-27 旭化成制药株式会社 弥散性血管内凝血综合征的治疗剂和/或改善剂
EP2129473B1 (en) 2007-03-28 2019-07-03 Medtronic ATS Medical, Inc. Method for inhibiting platelet interaction with biomaterial surfaces
AU2008300516A1 (en) * 2007-09-20 2009-03-26 Bracco Imaging Spa Method for the preparation of new oligoclonal antibodies
MY162546A (en) 2007-12-05 2017-06-15 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
WO2009086552A1 (en) * 2008-01-02 2009-07-09 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
JP5529869B2 (ja) * 2008-08-14 2014-06-25 メルク・シャープ・アンド・ドーム・コーポレーション プロテインａアフィニティークロマトグラフィーを用いる抗体の精製方法
WO2010045518A1 (en) * 2008-10-16 2010-04-22 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2230251A1 (en) * 2009-03-19 2010-09-22 Bracco Imaging S.p.A Antibodies specifically active in the coronary plaque and method for their identification
WO2011026000A1 (en) * 2009-08-28 2011-03-03 Bayer Healthcare Llc Cofactors for thrombin activation of factor vii and uses thereof
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
WO2011152694A2 (en) 2010-06-04 2011-12-08 Sk Chemicals Co., Ltd. Fusion protein having factor vii activity
SMT201700547T1 (it) 2010-06-15 2018-01-11 Genmab As Coniugati di farmaco anticorpo umano contro il fattore tissutale
JP6234224B2 (ja) 2010-08-05 2017-11-22 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 血栓溶解及び抗凝固特性を有するタンパク質融合構築物
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
WO2016167263A1 (ja) 2015-04-14 2016-10-20 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
ES3036076T3 (en) 2015-04-14 2025-09-12 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
WO2016176440A2 (en) * 2015-04-28 2016-11-03 Saint Louis University Thrombin-thrombomodulin fusion proteins as protein c activators
WO2017189943A1 (en) * 2016-04-28 2017-11-02 Saint Louis University Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant
BR112019010034A2 (pt) * 2016-11-16 2019-09-03 Bayer Healthcare Llc fator viii alvejado de hemácia e método de uso do mesmo
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
UA130009C2 (uk) 2018-05-07 2025-10-15 Генмаб А/С Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу
WO2020070237A1 (en) * 2018-10-04 2020-04-09 Thrombosis And Coagulation Ab Method for the determination of protein s levels
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos
CN114686444B (zh) * 2020-12-31 2024-05-31 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用
CN114686443B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US4912207A (en) 1987-05-06 1990-03-27 Washington University DNA clone of human thrombomodulin and portions thereof
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
EP0458903A4 (en) * 1989-02-17 1992-06-17 Codon Soluble analogs of thrombomodulin
US6063763A (en) 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US5466668A (en) 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
US5256770A (en) 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
KR930008093B1 (ko) 1990-08-03 1993-08-25 아사히가세이고오교 가부시끼가이샤 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
JPH0578397A (ja) * 1991-01-29 1993-03-30 Sumitomo Pharmaceut Co Ltd 血栓溶解タンパク質
JPH06133780A (ja) * 1992-10-23 1994-05-17 Sumitomo Pharmaceut Co Ltd 新規なｔ−ＰＡ改変体
US5916874A (en) 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
JP3998419B2 (ja) * 1998-04-03 2007-10-24 中外製薬株式会社 ヒト組織因子（ｔｆ）に対するヒト型化抗体およびヒト型化抗体の作製方法
CA2402596A1 (en) * 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US6632791B1 (en) * 2000-06-21 2003-10-14 Schering Aktiengesellschaft Thrombomodulin analogs for pharmaceutical use
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
EP1978108A3 (en) 2002-01-08 2009-01-07 Siemens Healthcare Diagnostics GmbH Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
BR0304660A (pt) * 2002-05-01 2005-06-07 Schering Ag Anticorpos direcionados a fator de tecido como anticoagulantes
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants

Also Published As

Publication number Publication date
US7250168B2 (en) 2007-07-31
JP2005538046A (ja) 2005-12-15
WO2003093422A3 (en) 2004-07-15
BR0304659A (pt) 2004-09-21
AU2003225256B2 (en) 2009-06-04
ZA200409692B (en) 2006-07-26
UA81114C2 (en) 2007-12-10
DE60334538D1 (de) 2010-11-25
RS102404A (sr) 2006-12-15
KR101080587B1 (ko) 2011-11-04
ATE427121T1 (de) 2009-04-15
BR0304660A (pt) 2005-06-07
AU2003225256A1 (en) 2003-11-17
NZ536242A (en) 2006-04-28
IL164733A0 (en) 2005-12-18
ATE484524T1 (de) 2010-10-15
WO2003092602A3 (en) 2004-08-26
CN100412090C (zh) 2008-08-20
WO2003093422A2 (en) 2003-11-13
WO2003092602A2 (en) 2003-11-13
RS104504A (sr) 2007-02-05
US20080019985A1 (en) 2008-01-24
HK1080372A1 (zh) 2006-04-28
CR7584A (es) 2006-05-30
AU2003225255B2 (en) 2008-07-31
TWI343388B (en) 2011-06-11
ES2323056T3 (es) 2009-07-06
EP1549341A4 (en) 2006-10-18
AR039515A1 (es) 2005-02-23
IL164732A0 (en) 2005-12-18
EP1503785A2 (en) 2005-02-09
DE60326970D1 (de) 2009-05-14
JP4567437B2 (ja) 2010-10-20
US20080020965A1 (en) 2008-01-24
DK1549341T3 (da) 2009-07-06
DK1503785T3 (da) 2011-02-07
JP4460443B2 (ja) 2010-05-12
RU2004135308A (ru) 2005-08-10
CN100563709C (zh) 2009-12-02
US7622457B2 (en) 2009-11-24
IL164733A (en) 2011-05-31
RU2320366C2 (ru) 2008-03-27
PL373945A1 (en) 2005-09-19
PE20040597A1 (es) 2004-10-06
MXPA04010851A (es) 2005-02-14
KR20050045944A (ko) 2005-05-17
PL210582B1 (pl) 2012-02-29
ES2354419T3 (es) 2011-03-14
EP1549341B1 (en) 2009-04-01
EP1503785B1 (en) 2010-10-13
ZA200409694B (en) 2006-02-22
RU2345789C2 (ru) 2009-02-10
KR101013697B1 (ko) 2011-02-10
NO20035849L (no) 2004-02-27
AU2003225255A1 (en) 2003-11-17
EP1549341A2 (en) 2005-07-06
JP2005532045A (ja) 2005-10-27
MXPA04010795A (es) 2005-03-07
TW200307043A (en) 2003-12-01
NZ536243A (en) 2006-06-30
UA85996C2 (ru) 2009-03-25
CN1665534A (zh) 2005-09-07
PT1503785E (pt) 2011-01-17
CN1665526A (zh) 2005-09-07
EP1503785A4 (en) 2007-02-14
KR20050045945A (ko) 2005-05-17
CA2483910A1 (en) 2003-11-13
ECSP045468A (es) 2005-01-28
CA2483909A1 (en) 2003-11-13
US7622122B2 (en) 2009-11-24
PL373960A1 (en) 2005-09-19
US20040063632A1 (en) 2004-04-01
PT1549341E (pt) 2009-05-29
RU2004135306A (ru) 2005-07-10
ECSP045467A (es) 2005-01-28

Similar Documents

Publication Publication Date Title
NO20035848L (no) Nye vevsfaktorrettede antistoffer som antikoagulanter
NO20044588L (no) Nye forbindelser
NO20044432L (no) Nye forbindelser
DK1523493T3 (da) Nye tubulysinanaloge
DE50308694D1 (de) Bestrahlungsger t
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
NO20055219D0 (no) Nye forbindelser
DE60336213D1 (de) Chirurgisches klammergerät
NO20054005D0 (no) Nye arylpiperazinylforbindelser
EP1664117A4 (en) IMMUNOGENIC
DE50302584D1 (de) Stereomikroskop
DE50302514D1 (de) Stereomikroskop
DK1556377T3 (da) Cyclopropylthienylcarboxamider som fungicider
DE50303208D1 (de) Osteosyntheseeinrichtung
ITPS20030026A1 (it) Struttura di osteotomo.
NO20026285D0 (no) Nye peptider
DE502004005544D1 (de) Mikrodosiereinrichtung
DE50303886D1 (de) Tragarm
DE60325211D1 (de) Lichtstrahlformvorrichtung
NO20044098L (no) Nye forbindelser
EP1579918A4 (en) EXTRACTORS
NO20043215L (no) Nye alkansulfonamider som endothelin-antagonister
DE60315020D1 (de) (2s)-2-ethylphenylpropionsäurederivat
ITMI20020227A0 (it) Procedimento per la preparazione di alchiluree da o ,d-dimetil ditiocarbonato
AT500592B8 (de) Entstörgerät

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application